Durable and Treatment-Agnostic PTK7 Expression in EGFR-Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development

IASLC WCLC 2026

Aug 19, 2026
Oncology
Presentation

A. Lisberg, A. Dowlati, M.M. Mirsky, C.S. Baik, L. Deng, D. Delgado, L. Langouche, K.S. Keegan, D. Dornan, A.B. Pai, M. Dugan, D.J. Lennon, G.K. Dy

Introduction
Protein tyrosine kinase 7 (PTK7), a catalytically inactive receptor tyrosine kinase, is aberrantly overexpressed in various malignancies and, in some tumor types, contributes to tumor progression, metastasis, and chemoresistance. A previous analysis showed high PTK7 expression across histologic subtypes and disease stages of non-small cell lung cancer (NSCLC), irrespective of epidermal growth factor receptor (EGFR) mutation status, supporting PTK7 as a promising antibody-drug conjugate (ADC) target. This study aimed to assess PTK7 expression pre- and post-standard-of-care treatment, and relative to other ADC targets, in EGFR-wild-type lung adenocarcinoma.

 

Methods
RNA sequencing data from a real-world database (Tempus AI, Inc.) were used to examine PTK7 mRNA expression in pre- versus post-treatment tumor samples from patients with advanced unresectable (stage 3B/3C)/metastatic EGFR-wild-type lung adenocarcinoma treated with standard therapies. The effect of other actionable genetic alterations (AGAs) on PTK7 expression was also assessed. Median PTK7 expression was quantified as log2(transcripts per million [TPM]+1). Group differences were analyzed using the Wilcoxon test. Co-expression of PTK7 with other ADC targets was evaluated using Spearman’s correlation.

 

Results
The analysis included 7856 EGFR-wild-type lung adenocarcinoma tumor samples. PTK7 expression remained stable after most standard-of-care treatments including chemotherapy and immunotherapy (Figure 1). Other ADC targets (ie, MET, Iβ6, PD-L1 and NaPi2b) showed greater and more variable treatment-associated expression changes than PTK7 across standard-of-care therapies (Figure 1). There was minimal change in median PTK7 expression with wild-type versus mutated KRAS (6.6 vs 6.6), ALK (6.6 vs 6.5), and MET (6.6 vs 6.6). PTK7 expression was moderately correlated with CD276 (B7‑H3; ρ=0.34). There was a negligible correlation between PTK7 expression and the expression of other therapeutic targets, including EGFR (Spearman’s rho [ρ]=0.12), TACSTD2 (Trop-2; ρ=0.09), ERBB3 (HER3; ρ=0.04), and CD274 (PD-L1; ρ=-0.08).

 

Conclusions
PTK7 expression is highly stable over time, with minimal pre- to post-treatment changes across standard therapies for EGFR-wild-type lung adenocarcinoma. PTK7 shows lower variation in pre- to post-treatment expression compared with other ADC targets, indicating low susceptibility to therapy-induced modulation. In EGFR-wild-type lung adenocarcinoma, PTK7 expression is largely independent of that of other AGAs, suggesting a distinct patient population may benefit from PTK7-targeted therapy. HWK-007, a next-generation, PTK7-directed ADC, is currently being evaluated in a phase 1 clinical trial (NCT07444814) in patients with solid tumors, including non-squamous EGFR-wild-type NSCLC.